Content provided in partnership with
Technology Industry
Industry: Email Alert RSS FeedBiolex Therapeutics of Pittsboro closed on a $30 million Series C financing led by Investor Growth Capital of New York and including two other new investors, JP Morgan Securities and Easton Capital
BT Catalyst, July-August, 2007
Biolex Therapeutics of Pittsboro closed on a $30 million Series C financing led by Investor Growth Capital of New York and including two other new investors, JP Morgan Securities and Easton Capital, as well as existing shareholders including Quaker BioVentures, Polaris Venture Partners, Intersouth Partners, Mitsui & Co.
- Most Popular Articles in Technology
- An overview of continuous data protection
- Why all those current ratings?
- Many countries now have a mobile penetration rate above 100%, report says
- The Tata Group's big telecom gamble: VSNL's recent acquisition of Tyco ...
- MEASURING BANK BRANCH EFFICIENCY USING DATA ENVELOPMENT ANALYSIS: MANAGERIAL ...
- More »
Venture Partners, Johnson & Johnson Development Corporation and Dow Venture Capital. The funds will be used primarily to advance Biolex's lead drug candidate Locteron into phase 3 clinical development in hepatitis C, and to advance the company's other drug candidates.
COPYRIGHT 2007 North Carolina Biotechnology Center
COPYRIGHT 2007 Gale Group
Find Research Guides for:
Find Featured Titles for: Home & Garden
Most Popular Articles in Technology
- An overview of continuous data protection
- Why all those current ratings?
- Many countries now have a mobile penetration rate above 100%, report says
- The Tata Group's big telecom gamble: VSNL's recent acquisition of Tyco ...
- MEASURING BANK BRANCH EFFICIENCY USING DATA ENVELOPMENT ANALYSIS: MANAGERIAL ...
- More »